Shanghai – September 26, 2026 -- IASO Biotechnology's CAR-T therapy FUCASO achieved a 95.9% objective response rate and 77.2% complete/stringent complete response rate in a real-world study of 281 heavily pretreated Chinese patients with relapsed or refractory plasma cell neoplasms, data presented at the 2026 International Myeloma Society Annual Meeting show.

Shanghai – September 25, 2026 -- IASO Biotechnology reported an 88.9% objective response rate for its dual-targeted CAR-T therapy RD140 in a first-in-human Phase 1 trial of nine heavily pretreated multiple myeloma and plasma cell leukemia patients, with the response rate reaching 100% in the higher-dose cohort.

Raritan, N.J. – September 25, 2026 -- Half of patients with early-line relapsed or refractory multiple myeloma treated with a single infusion of Johnson & Johnson's CARVYKTI® (ciltacabtagene autoleucel) remained alive and progression-free for at least five years without maintenance therapy, according to new long-term data from the Phase 2 CARTITUDE-2 study.

Rockville, Md. – September 24, 2026 -- REGENXBIO Inc. (Nasdaq: RGNX) reported that 60% of Dose Level 3 participants with three-year follow-up data in its Phase II ALTITUDE study achieved a greater-than-2-step improvement on the Diabetic Retinopathy Severity Scale (DRSS) after a single in-office treatment with investigational gene therapy sura-vec, with no vision-threatening events recorded among responders.

Dover, Del. – September 24, 2026 -- Clywedog Therapeutics, Inc. reported that its investigational menin inhibitor balomenib produced a placebo-adjusted mean HbA1c reduction of 0.77% at Week 12 (p0.01) and 0.70% at Week 16 (p0.05) in a Phase 1b trial, effects recorded three months after the drug's final dose following just three weeks of treatment.

Boston – September 23, 2026 -- CSA Medical, Inc. announced publication in the American Journal of Respiratory and Critical Care Medicine of pivotal SPRAY-CB trial results showing its RejuvenAir System reduced severe COPD exacerbation rates by 38.4% versus a sham control.

Suzhou, China – September 23, 2026 -- Innovent Biologics (HKEX: 01801) will present late-breaking Phase 3 data for its CLDN18.2-targeting antibody-drug conjugate IBI343/TAK-921 at the 2026 European Society for Medical Oncology (ESMO) Annual Meeting in Madrid, running October 23-27.

New Taipei City – September 23, 2026 -- Caliway Biopharmaceuticals (TWSE: 6919) said on September 21 that its Phase 2 CBL-0202DD trial of CBL-514 met its primary efficacy endpoint, delivering statistically significant pain reduction in patients with Dercum's Disease compared with placebo, in both the Full Analysis Set (FAS) and Per-Protocol (PP) populations.

Hong Kong – September 21, 2026 -- Akeso, Inc. (9926.HK) will present nearly 30 clinical studies of its bispecific antibodies at the European Society for Medical Oncology (ESMO) Congress in Madrid on October 23-27, 2026, including a Late-Breaking Abstract selected for the Presidential Symposium.

Beijing – September 21, 2026 -- T-MAXIMUM Pharmaceutical reported that two of three evaluable patients with refractory brain metastases from lung cancer achieved partial responses with roughly 80% tumor shrinkage after treatment with its allogeneic B7-H3-targeted CAR-T therapy, MT027, according to early data presented at the IASLC World Conference on Lung Cancer (WCLC 2026) in Seoul.